30 d'octubre de 2019
Auditori PRBB (80:30 a 16:30)
El 30 d'octubre es farà a l'Auditori del PRBB la tercera edició del curs Optimizing Immunotherapy: New Approaches, Biomarkers, Sequences and Combinations.La inscripció és gratuïta i es farà per ordre d'inscripció.
El programa és el següent:
08:30 - 09:00 Registration
09:00 - 09:05 Welcome and opening. Joaquim Bellmunt
09:05 - 09:30 Combination immunotherapy: Challenges and Future Trends. Luis Álvarez-Vallina
09:30 - 11:00 TABLE 1. Immunotherapy in the clinic, focused on long term survival. Moderator: Alejo Rodríguez-Vida
09:30 - 09:45 Melanoma. Clara Montagut
09:50 - 10:05 Lung. Ernest Nadal
10:10 - 10:25 Genitourinary. Pablo Maroto
10:25 - 10:40 Other IO indications. Juan Martín Liberal
10:40 - 11:00 Discussion
11:00 - 11:20 Coffee
11:20 -13:40 TABLE 2. Biomarkers in immunotherapy. Moderator: Joan Albanell
11:20 - 11:35 PDL1 as a predictive biomarkers: pros and cons. Núria Juanpere
11:40 - 11:55 Predictive value of the Mutational load, neoantigens and clonal antigens. Somatic and germline genomic alterations. Ana Vivancos
12:00 - 12:15 RNA Signatures as predictive biomarker. Júlia Perera
12:20 - 12:35 Microbiome as predictor of benefit and toxicity. Guillem Arguiles
12:40 - 12:55 How to analyze genomic data for immunotherapy appliances. Núria López-Bigas
13:00 - 13:15 TMB. Blood based biomarkers. Liquid biopsy. Beatriz Bellosillo
13:20 - 13:40 Discussion
13:40 - 14:30 Lunch
14:30 -16:40 TABLE 3. Futures perspectives on immunotherapy. Moderator: Edurne Arriola
14:30 - 14:45 Combination and sequencing: with radiation therapy, with chemotherapy and with targered therapies. Josep Ma Piulats
14:50 - 15:05 CAR T-cells. Sonia Guedan
15:10 - 15:30 Discussion
15:35 - 15:50 New biomarkers in the IO era. Joaquim Bellmunt
15:55 - 16:30 First line treatment of RCC. Hans Hammers
16:30 Closing remarks. Joaquim Bellmunt
A/A Fernando Ochoa
T. 934 703 513
fochoa@meetingpharma.com
www.meetingpharma.com
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
